Alpha-MSH therapies for treatment of autoimmune disease
Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as ACTH. Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance methods for the oral treatment of multiple sclerosis with alpha-MSH and ACTH are described.
1. A method for treating or delaying the onset of multiple sclerosis in a subject comprising enterally administering to the subject an effective dose of an isolated alpha-MSH monomer, wherein the monomer consists of the amino acid sequence set forth in SEQ ID NO:2.
2. The method of claim 1 , wherein the alpha-MSH monomer is administered orally.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 1 , wherein the alpha-MSH monomer is blocked at the amino terminus, the carboxy terminus or both.
5. The method of claim 4 , wherein the alpha-MSH monomer is acetylated at the amino terminus and amidated at the carboxy terminus.
6. The method of claim 1 , wherein the alpha-MSH monomer is administered in a liquid form.
7. The method of claim 1 , wherein the alpha-MSH monomer is administered in a solid form.
8. The method of claim 1 , further comprising administering a second therapeutic agent before, after or concomitantly with the alpha-MSH monomer.
9. The method of claim 8 , wherein the second therapeutic agent is a soluble immune response suppressor (SIRS) polypeptide, an interferon polypeptide, or an anti-inflammatory agent.
10. The method of claim 8 , wherein the second therapeutic agent is administered orally.